

Fig. 1-A

1042220:ED+ZT660




Fig. 1-B




Fig. 1-C

10/22/20 09:47:66

Size: 0.6360 mg  
Method: 10 DEG C/MIN AMB TO 300  
Comment: SEALED PAN




Fig. 2-A

104220010H171660

Size: 1.7840 mg  
Method: 10 DEG C/MIN AMB TO 300  
Comment: SEALED PAN




Fig. 2-B

1012220-20H21660

Size: 1.4230 mg  
Method: 10 DEG C/MIN AMB TO 300  
Comment: SEALED PAN




Fig. 2-C

102220.E0171660

Size: 1.0400 mg  
Method: 10 DEG C/MIN AMB TO 300  
Comment: SEALED PAN




Fig. 2-D

10/22/03 07:27:01

Sample Weight 15.390 mg  
 Comment N-Propyl Alcohol sulfate 1  
 Unlabeled PDI




Fig. 2E



09917403-0/2/201




Fig. 3-A

09117403.072701  
102220"50471660




Fig. 3-B




Fig. 3-C




Fig. 3-D

09917403.072701  
T02220'30471660




Fig. 4

09917403.072701




Fig. 5




Fig 6-A

09917403.072220.E0471660




Fig. 7






Fig. 8

00471660 10.2220




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15








Fig. 16



Interaction of A: Cooling Rate and B: Purity

Fig. 17



Cooling Rate  
Fig. 18




Fig. 19




Fig. 20

090740\* 00471660




Fig. 21





Fig. 22

**Fig. 23**  
**Study Schematic**








**Fig. 25**  
**Baseline Weight, BP, Heart Rate**


<b>BB</b>	
<b>Mean Values</b>	
	<b>Pbo</b> (N = 66)
	<b>Epl</b> (N = 69)
<b>Weight (kg)</b>	
Female	70.4
Male	88.9
	82.0
	84.2
<b>BP (mmHg)</b>	
SBP / DBP	157.2 / 98.8
	158.2 / 99.0
<b>Heart Rate (bpm)</b>	
	65.7
	68.7

**Fig. 26**  
**Mean Change From Baseline in BP**  
**Week 8 (Final Visit)**




\*Adjusted to treatment, center, and baseline value

**Fig. 27**  
**Mean Change in BP (Each Visit):**  
**BB and Eplerenone**



\*Adjusted to treatment, center, and baseline value

**Fig. 28**  
**Active Renin and Aldosterone:**  
**BB and Eplerenone**



**Fig. 29**  
**Adverse Events**

<b>Adverse Events</b>	<b>BB</b>	
	<b>Pbo</b> (N = 66)	<b>Epl</b> (N = 69)
Hyperkalemia	0	4*
Hyperuricemia	0	0
Increased Lab Values		
GGT	0	0
SGOT	0	0
SGPT	0	0
BUN	0	0
Impotence	0	0
Gynecomastia	0	0
Hypotension	0	0
Menstrual Irregularities	0	0

\* 3 cases of hyperkalemia resolved spontaneously with continued treatment, and one patient was withdrawn